{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:23:35Z","timestamp":1791300215954,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cancergen.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T12:30:06Z","timestamp":1471264206000},"page":"403-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers"],"prefix":"10.1016","volume":"209","author":[{"given":"Tracey P.","family":"Leedom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"LaDuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S.","family":"Dolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2016.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1086\/421251","article-title":"CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies","volume":"74","author":"Consortium CBCC-C.","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0015","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ejca.2011.03.025","article-title":"Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility","volume":"47","author":"Xiang","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0020","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0025","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1158\/0008-5472.CAN-04-0341","article-title":"A novel founder CHEK2 mutation is associated with increased prostate cancer risk","volume":"64","author":"Cybulski","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jmg.2006.044974","article-title":"A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer","volume":"43","author":"Cybulski","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0035","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-008-0249-1","article-title":"Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk","volume":"117","author":"Serrano-Fernandez","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10689-012-9599-2","article-title":"The risk of gastric cancer in carriers of CHEK2 mutations","volume":"12","author":"Teodorczyk","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.21022","article-title":"Association of two mutations in the CHEK2 gene with breast cancer","volume":"116","author":"Bogdanova","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ijc.20299","article-title":"CHEK2 variant I157T may be associated with increased breast cancer risk","volume":"111","author":"Kilpivaara","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","article-title":"Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population","volume":"14","author":"Shaag","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0065","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","article-title":"Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer","volume":"22","author":"Kapoor","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2015.01.537","article-title":"Hereditary predisposition to ovarian cancer, looking beyond BRCA1\/BRCA2","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0080","first-page":"823","article-title":"Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing","volume":"18","author":"Susswein","year":"2016","journal-title":"Gen Med"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0085","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0090","first-page":"830","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2000 patients","volume":"16","author":"Laduca","year":"2014","journal-title":"Gen Med"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.cancergen.2016.08.005_bib0100","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776216302290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776216302290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:41:31Z","timestamp":1761896491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776216302290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2210776216302290"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2016.08.005","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}